- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Branch retinal vein occlusion with macular oedema; Central retinal vein occlusion with macular oedema; Diabetic macular oedema; Subfoveal choroidal neovascularisation due to age-related macular degeneration
- Meeting Date: July 2026
Aflibercept – July 2026
- Solution for intravitreal injection 3.6 mg in 90 microlitres (40 mg per mL) pre-filled syringe
- Solution for intravitreal injection 4 mg in 100 microlitres (40 mg per mL)
Last updated
20 November 2026
